Internal ribosome entry site (IRES)-mediated translation of input viral RNA is the initial required step for the replication of the positive-stranded genome of hepatitis C virus (HCV). We have shown previously the importance of the GCAC sequence near the initiator AUG within the stem and loop IV (SLIV) region in mediating ribosome assembly on HCV RNA. Here, we demonstrate selective inhibition of HCV-IRES-mediated translation using short hairpin (sh)RNA targeting the same site within the HCV IRES. sh-SLIV showed significant inhibition of viral RNA replication in a human hepatocellular carcinoma (Huh7) cell line harbouring a HCV monocistronic replicon. More importantly, co-transfection of infectious HCV-H77s RNA and sh-SLIV in Huh7.5 cells successfully demonstrated a significant decrease in viral RNA in HCV cell culture. Additionally, we report, for the first time, the targeted delivery of sh-SLIV RNA into mice liver using Sendai virosomes and demonstrate selective inhibition of HCV-IRES-mediated translation. Results provide the proof of concept that Sendai virosomes could be used for the efficient delivery of shRNAs into liver tissue to block HCV replication.
INTRODUCTION
Hepatitis C virus (HCV) has infected over 180 million people and the majority of them are at risk of developing liver cirrhosis and/or hepatocellular carcinoma (Saito et al., 1990) . The current treatment regimen available for HCV infection includes pegylated-interferon-a in combination with ribavirin, which has limitations in its efficacy, as many patients don't respond to this therapy (Iwasaki et al., 2006) , and also results in unwanted side effects. There is therefore an urgent need to develop an effective and specific antiviral for combating HCV disease progression. Several approaches targeting different regions of the viral genome are being investigated, such as serine-protease inhibitors, monoclonal antibodies, anti-fibrotics, immunosuppressants and immunomodulators (Pawlotsky et al., 2007; Tan et al., 2002) . There are initiatives to develop nucleic acid-based antiviral agents, such as short hairpin (sh)RNA, short interfering (si)RNA, ribozymes and DNAzymes targeting non-coding regions, structural and non-structural proteins, which have shown moderate or better inhibition at the level of protein synthesis and replication (Trepanier et al., 2006) .
The synthesis of HCV proteins is mediated by the 59 capindependent internal initiation mechanism, where the loading of the ribosome onto HCV RNA is mediated through a highly structured RNA element, the internal ribosome entry site (IRES) (Wang et al., 1993) . Since the mechanism of ribosome assembly is unique and fundamentally different from the cap-dependent translation of the host cell mRNA, it can be targeted to selectively inhibit viral protein synthesis and consequently its replication (Dasgupta et al., 2004; Hellen & Sarnow, 2001; Trowbridge & Gowans, 1998) . Previously, we have demonstrated the importance of the GCAC sequence near the iAUG for ribosome assembly onto HCV IRES RNA (Pudi et al., 2003 (Pudi et al., , 2005 . In fact, human La protein (an important host factor) has been shown to bind to the above sites and a peptide derived from the RNA-binding region of La protein has been shown to interfere with the ribosome assembly and inhibit viral RNA translation (Ali et al., 2000; Mondal et al., 2008; Pudi et al., 2004 Pudi et al., , 2005 . Here, we have investigated the ability of an shRNA targeting this region of HCV IRES to inhibit translation and replication of viral RNA. peptides etc. (Dasgupta et al., 2004; Pawlotsky et al., 2007; Roy et al., 2008) . However, to date, a suitable system for selective and efficient delivery of small nucleic acid molecules into liver cells is lacking. F-virosomes derived from Sendai virus have been shown to be capable of liver-specific membrane-fusion-mediated delivery of drugs/genes to hepatocytes. It has been well established that these virosomes are selectively targeted to the hepatocytes of mice both in vitro and in vivo (Bagai et al., 1993; Nijhara et al., 2001; Ramani et al., 1998) . Thus, in this study we have exploited the F-virosomal delivery of shRNA for its targeted expression and report for the first time the targeted delivery of HCV-specific shRNA into mouse liver as a proof of concept to demonstrate significant inhibition of HCV IRES-mediated translation in vivo using mice.
METHODS
Plasmid constructs. A relatively conserved and unique sequence within HCV IRES was selected to construct shRNA lacking homology with cellular genes. shRNA oligonucleotides were designed to contain a sense strand of 19 nt, followed by a short spacer (TTCAAGAGA), the reverse complement of the sense strand and five thymidines as a stop signal. sh-Stem and loop IV (SLIV) was designed by targeting the HCV IRES corresponding to nt 331-350. Additionally, to generate a non-specific control shRNA (Nsp-sh) a non-specific sequence was also cloned in the poly-linker region of the pSUPER vector. The target sequence of sh-SLIV is 59-GACCGUGCACCAUGAGCAC-39 and of Nsp-shRNA is 59-CAGUCGCGUUUGCGACUGG-39. To clone the shRNA-encoding DNA sequences, sense and antisense strand oligonucleotides corresponding to the target sequences were denatured at 95 uC and annealed by gradually cooling to 4 uC; these were then cloned into the BglII and HindIII sites of pSUPER vector (Brummelkamp et al., 2002) . The bicistronic plasmid construct (RLuc-HCV-IRES-FLuc) containing HCV IRES in between renilla luciferase (Rluc) and firefly luciferase (Fluc) genes was cloned into the pCDNA3.1 vector. In this bicistronic construct, the Rluc reporter gene represents the cap-dependent translation, whereas Fluc translation is mediated by the HCV IRES (Pudi et al., 2003) . Similarly, the Coxsackievirus B3 (CVB3) bicistronic construct, which contains the CVB3 IRES between Rluc and Fluc (Bhattacharyya et al., 2008) , was used as a non-specific IRES control. pSV-b-gal plasmid (Promega) was used as a control reporter plasmid for normalizing transfection efficiency. pSUPER vector alone (without shRNA) was used as a control.
Cell cultures. Human hepatocellular carcinoma (Huh) 7 and Huh7.5 cell monolayers were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % heat-inactivated fetal bovine serum (FBS) at 37 uC in 5 % CO 2 . To cells harbouring the HCV monocistronic replicon (a kind gift from Dr Ralf Bartenschlager, Heidelberg University, Germany), 25 mg hygromycin B ml 21 was added to the culture medium (Frese et al., 2003) .
Transient co-transfection of shRNA. Monolayers (70 % confluent) of Huh7 cells in 35 mm dishes were co-transfected with the shRNA plasmid construct and the HCV bicistronic plasmid DNAs or the CVB3 bicistronic construct along with a b-galactosidase (b-gal) construct using Tfx20 transfection reagent (Promega). Cells were harvested 24 h post-infection using passive lysis buffer (Promega) and Fluc and Rluc activities were measured using the Dual Luciferase assay system (Promega) in a TD 20/20 Luminometer (Turner Designs); the activities were normalized with respect to b-gal expression of the cells.
A cell culture-adapted infectious H77s-cDNA construct (a generous gift from Stanley Lemon, University of Texas, Galveston, USA) was used to generate H77s RNA after linearization with XbaI followed by run-off transcription. The respective shRNA constructs (0.5 mM) and the infectious H77s RNA (0.4 mM) were co-transfected into Huh7.5 cells using Lipofectamine 2000 (Invitrogen). Total cellular RNA was extracted 72 h post-transfection (p.t.) and quantitative RT-PCR (qRT-PCR) was performed.
shRNA transfection in Huh7 cells harbouring the HCV replicon.
Transfection of shDNA constructs into cells harbouring HCV replicons was performed as described previously (Roy et al., 2008) . Briefly, Huh7 cells harbouring the monocistronic HCV (genotype 2a) replicon, were transfected with either pSUPER vector (a generous gift from Dr Rene Bernards, Netherlands) alone (as control) or with 0.5 mM of the plasmid constructs encoding sh-SLIV or Nsp-sh RNA.
Total RNA was isolated 48 h p.t. using Tri Reagent (Sigma) and RT-PCR was carried out as stated below. For the colony formation assay, cells were trypsinized 24 h p.t. and 4610 3 cells were seeded in 35 mm dishes, incubated for 10 days in the presence of 25 mg hygromycin B ml
21
. The cells were fixed with 90 % acetone, stained with Brilliant Blue G-250 in 40 % methanol and 10 % acetic acid; colonies were counted and the approximate percentage c.f.u. was calculated compared with the control.
Semiquantitative RT-PCR analysis. Semiquantitative RT-PCR was performed for HCV IRES positive and negative strand RNAs using standard protocols, as described previously (Roy et al., 2008) . The PCR products were analysed on 1.2 % agarose gels. cDNA synthesis from the positive and negative strands was performed using strandspecific primers. GAPDH was also amplified using the relevant primer as an internal control in the same reaction. Quantification of the replicon RNA was performed by real-time PCR analysis of the respective cDNAs synthesized using the qRT-PCR SYBR green kit (Finnzymes) following the manufacturer's protocol, using an Applied Biosystems 7900HT machine.
Sendai virus culture and preparation of plasmid DNA-loaded Fvirosomes. Sendai virus (Z strain) was grown in 10-11-day-old embryonated chicken eggs, harvested and purified by following published protocols (Bagai et al., 1993) . Viral yield was estimated in terms of protein and its fusogenic activity was checked. Reconstituted Sendai viral envelopes containing the F-protein (F-virosomes) were prepared as described by Bagai et al. (1993) and Ramani et al. (1998) . Briefly, 100 mg Sendai virus envelope was reduced with 3 mM DTT at 37 uC followed by dialysis to remove haemagglutinin neuraminidase (HN) protein. The suspension was finally resuspended in nonionic detergent for 1 h; this resulted in removal of HN as well as the viral genetic material containing the RNA genome. The supernatant from the detergent extract was mixed with the desired plasmid DNA (HCV bicistronic DNA construct with or without shRNA constructs) and reconstituted by stepwise removal of detergent using SM-2 Biobeads (Bio-Rad). The final virosome pellet was suspended in 10 mM PBS.
Fusion-mediated delivery of plasmids to cell lines. Monolayers of Huh7 cells (in 12-well culture plates; Falcon) were washed twice with 1 ml DMEM without serum. Cells were incubated with loaded F-virosomes (0.3 mg F-protein) containing 3-4 mg HCV bicistronic plasmid construct with or without sh-SLIV or Nsp-sh plasmid at 37 uC at 5 % CO 2 in 2 ml serum-free medium. Cells alone were used as controls. After 2 h of fusion, medium was replaced with DMEM containing 10 % FBS and cells were further incubated for 24 h at 37 uC at 5 % CO 2 . The luciferase reporter assay was performed as stated above.
Administration of loaded virosomes to BALB/c mice. Twelveweek-old male BALB/c mice were maintained under specific pathogen-free conditions in the animal facility. These BALB/c mice (~20 g) were given two injections (at an interval of 24 h) intravenously into the tail vein. The injection consisted of HCV bicistronic plasmid with or without sh-SLIV or Nsp-sh plasmidloaded F-virosomes (containing 4 mg DNA) in a final volume of 0.2 ml Tris-buffered saline containing 2 mM Ca 2+ . The equivalent volume of PBS was injected as a control (with or without the same amount of free DNA). Two days post-injection, animals were sacrificed for hepatocyte isolation.
Isolation and gene expression in isolated hepatocytes. Liver parenchymal cells were isolated by collagenase perfusion of the liver following a standard procedure (Nijhara et al., 2001) . Briefly, the perfused liver was excised from the animal, cut into small pieces and washed thoroughly with phosphate buffer, pH 7.4. The liver pieces were incubated at 37 uC for 30 min in a buffer containing collagenase A (hepatocyte qualified; Gibco). The resulting liver mass was filtered through a nylon mesh and the filtrate was centrifuged at 500 g for 10 min at 4 uC to obtain a pellet containing the hepatocytes. The non-hepatocyte pellet was obtained by centrifuging the supernatant at 1500 g for 10 min at 4 uC. Both of these cell types were washed three times with ice-cold PBS, pH 7.4, lysed with passive lysis buffer (Promega) and the cell extracts were then subjected to a dual luciferase assay.
Statistical analysis. All statistical analyses were performed using Student's t-test. All graphs represent mean±SD. P-values were determined by using a paired t-test. P-values of less than 0.01 were considered to be statistically significant.
RESULTS
Inhibition of HCV RNA translation by shRNA targeting the IRES element Specific shRNA targeting SLIV (encompassing the GCAC and the iAUG sequence) of the HCV IRES (Fig. 1) has been designed and cloned into pSUPER vector (Brummelkamp et al., 2002) to generate sh-SLIV. A non-specific sequence was also cloned in the poly-linker region of the pSUPER vector to generate Nsp-sh. A range of concentrations of the sh-SLIV construct were co-transfected with the HCV bicistronic contruct (RLuc-HCV-IRES-FLuc) and pSV40 b-gal plasmid DNA and the luciferase activity was measured in cells harvested 24 h p.t. The luciferase activities were normalized to the protein concentration of the lysates and the b-gal activity for the transfection efficiency (Fig. 1b) .
Our results showed that there was significant inhibition of HCV-IRES-mediated translation upon transfection of Huh7 cells with sh-SLIV (Fig. 2a) . However, Nsp-sh did not significantly inhibit HCV-IRES-mediated translation. To further demonstrate the specificity of sh-SLIV function, a similar experiment was performed using the bicistronic construct containing the IRES element of CVB3. These data showed that there was no significant inhibition of CVB3 translation by HCV-specific shRNA (Fig. 2b) , reconfirming the target specificity of the sh-SLIV for the HCV IRES RNA.
Effect of sh-SLIV RNA on HCV replication in replicon cell line and in HCV cell culture
To investigate the effect of the sh-SLIV on HCV RNA replication, sh-SLIV, Nsp-sh or pSuper vector control DNA was transfected into Huh7 cells harbouring the HCVmonocistronic replicon, maintained with hygromycin B (Frese et al., 2003) (Fig. 3a) . Total cellular RNA was isolated 48 h p.t. Semiquantitative RT-PCR analysis of RNA iolated 48 h p.t. indicated that there was considerable inhibition of both positive-and negative-strand synthesis (Fig. 3b) . To reconfirm these data, the replicon RNA was quantified by real-time PCR analysis. The results showed shRNA targeting HCV RNA significant inhibition of both positive (2.25-fold decrease, 80 % inhibition) and negative (3.1-fold decrease, 90 % inhibition) strands when transfected with the sh-SLIV construct. In contrast, the Nsp-shRNA showed only marginal inhibition (Fig. 3c) .
As the inhibition was between 80 and 90 %, we intended to determine whether the shRNAs completely eliminate viral RNA in a given cell. The efficacy of shRNA for curing of replicating HCV RNA in Huh7 cells at the single cell level was assessed by colony formation assay. This showed that around 97 % of cells were virus free or survived in the presence of sh-SLIV compared with the control or NspshRNA (~3 %) (Fig. 3d) .
To evaluate the efficacy of sh-SLIV RNA to inhibit HCV replication in cell culture, HCV-H77s RNA was generated from a cell culture-adapted infectious H77s-cDNA construct ( Fig. 4a) (Yi et al., 2006) . Co-transfection of shRNA constructs and infectious H77s RNA resulted in a considerable inhibition of both the strands of HCV RNA. The positive strand was inhibited by 3.4-fold (93 %) and the negative strand was inhibited by 2.7-fold (80 %). However, the Nsp-sh or pSUPER vector did not show notable inhibition of either strand (Fig. 4b) .
Effect of virosome-loaded sh-SLIV RNA ex vivo in Huh7 cells and in vivo in BALB/c mice
To explore a suitable delivery system for the shRNA constructs, we opted to use Sendai virosomes, which are popular for selective and effective delivery into liver cells (Ramani et al., 1998) . Fig. 5(a) represents the process used for preparation of virosomes loaded with shRNA construct. The engineered virosome and the delivery strategy in BALB/c mice are shown in Supplementary Fig. S1 (available in JGV Online). Essentially, the engineered Sendai virosomes (suitable for the delivery of the shRNAs) were packed with HCV bicistronic DNA construct with or without shRNA construct and used for transfection into Huh7 cells and BALB/c mice. In order to achieve a systematic assessment of the ability of Fvirosome-mediated delivery of this shRNA and its ability to inhibit HCV IRES in a liver-derived cell line, monolayers of Huh7 cells were transfected with virosomes loaded with HCV bicistronic construct and sh-SLIV or Nsp-sh construct. Luciferase activity was measured 24 h p.t. Significant inhibition (~80 %) of HCV-IRES-mediated translation was observed in the presence of the sh-SLIV compared with the control. However, Nsp-sh showed very little or negligible inhibition of HCV-IRES-mediated translation (Fig. 5b) . The results suggest that there is efficient delivery of the virosome-entrapped shRNA constructs inside liver-derived Huh7 cells and selective inhibition of HCV-IRES-mediated translation. We have also tried the experiment of separate trapping of HCVbicistronic DNA and the sh-SLIV construct in the virosomes; subsequent delivery to Huh7 cells showed only 16-20 % inhibition ( Supplementary Fig. S2 , available in JGV Online).
To investigate whether the Sendai virosomes packed with reporter gene constructs could deliver the DNAs selectively into liver cells in the context of the whole animal (BALB/c mouse), we first tested the preferential expression of luciferase gene loaded into Sendai F-virosome by intravenous (i.v.) injection through the tail vein. It was observed that the expression of the luciferase reporter gene occurred preferentially in the parenchymal cells (hepatocytes) of the mouse liver, compared with Kupffer cells (non-hepatocyte cells) (Fig. 6a) , which is consistent with an earlier publication (Ramani et al., 1998) . To assess the target specificity of F-virosomes to deliver sh-SLIV and inhibit HCV-IRES-mediated translation in vivo, F-virosomes containing HCV bicistronic construct and sh-SLIV or Nsp-sh encoding plasmids were delivered to BALB/c mice by using multiple i.v. injections through the tail vein. Livers from injected animals were analysed for luciferase activity. Mice treated with the sh-SLIV construct showed a significant reduction (75 %) in HCV-IRES-mediated translation of Fluc, compared with that in the control animal that received virosomes containing HCV bicistronic construct alone (Fig. 6b) . Free plasmid/buffer-injected animals showed no inhibition and served as an additional negative control (data not shown).
DISCUSSION
So far, several shRNAs targeting different regions of the HCV genome have been reported to achieve significant inhibition of translation and replication of viral RNA (Kanda et al., 2007; Kapadia et al., 2003; Randall et al., 2003; Wilson et al., 2003) . Some of the target sequences used were shown to be conserved across the genotypes. However, the scope of an siRNA-/shRNA-based antiviral strategy in general is limited because of the evolution of escape mutants. In this study, we purposely targeted the site (nt 331-350) within the SLIV region which encompasses cis-acting elements critical for ribosome assembly and which is likely to be more conserved in the HCV RNA and is protected from the generation of escape variants (Pudi et al., 2004) . Thus, the sh-SLIV could be used to achieve broad spectrum inhibition of HCV translation and replication.
Presumably, the sh-SLIV RNA inhibits HCV-IRES-mediated translation by cleaving the bicistronic RNA, as its sequence is exactly complementary to the target sequence. However, we do not rule out the possibility of any off-target activity by which shRNA might interfere with cellular factors critical for IRES function or induce double-stranded RNA-activated protein kinase, which in turn would contribute to inhibition of translation. sh-SLIV showed almost 80 % translation inhibition and up to 90 % replication inhibition of the replicon system and H77S RNA [full-length HCV genome that replicates and produces virus particles that are infectious in cell culture (HCVcc)] in an HCV cell culture assay, suggesting that sh-SLIV could be effective in inhibiting viral proliferation. Additionally, it would be interesting to use a cocktail of shRNAs (packed in a Sendai virosome) targeting different regions of the HCV genome to further potentiate the inhibitory activity.
Furthermore, in this study we have demonstrated targetspecific silencing of the HCV RNA using Sendai virus Fvirosomes, which are widely used for their liver specificity and efficient targeted delivery compared with cationic liposomes (Ramani et al., 1998) . Although several methods have been tried for the delivery of siRNA/shRNA molecules, which includes adenoviral and retroviral delivery systems (Kronke et al., 2004; Zhang et al., 2004) , none of these are selective for hepatocytes. Studies using mice as the animal model utilize tail vein injection or hydrodynamic injection for delivery of shRNAs, which requires a high dose as it is distributed systemically (Wang et al., 2005) . Therefore, the present delivery mode using Sendai virosomes can ensure targeted delivery into the mouse liver and could minimize the effective dose.
Finally, this study provides, for the first time, proof of concept for the targeted delivery of anti-HCV molecules into mouse liver cells using Sendai virosome, which could be a novel and effective delivery strategy to block HCV proliferation in liver tissue. 
